Grown Rogue International (GRUSF) Gains from Investment Securities (2015 - 2025)
Grown Rogue International (GRUSF) posted quarterly Gains from Investment Securities of -$6.9 million for Q2 2025, down 191.58% year-over-year from $7.5 million in Q2 2024, and down 689.44% quarter-over-quarter from $1.2 million in Q1 2025.
Grown Rogue International (GRUSF) Gains from Investment Securities (2015 - 2025) Analysis & Trends
Grown Rogue International's Gains from Investment Securities history runs 7 years deep, the most recent figure standing at -$6.9 million for Q2 2025.
- In Q2 2025, Gains from Investment Securities fell 191.58% year-over-year to -$6.9 million; the TTM figure through Jun 2025 stood at $2.2 million (down 88.15% YoY), while the FY2023 annual figure was $4.6 million, changed N/A from the prior year.
- Gains from Investment Securities for Q2 2025 stood at -$6.9 million, down from $1.2 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $7.5 million in Q2 2024, with the low at -$6.9 million in Q2 2025.
- The 4-year median for Gains from Investment Securities is $422867.0 (2021), against an average of $1.2 million.
- The sharpest annual moves came in 2021 and 2025: Gains from Investment Securities surged 712.28% in 2021, then tumbled 191.58% in 2025.
- Grown Rogue International's Gains from Investment Securities stood at $422867.0 in 2021, then surged by 979.18% to $4.6 million in 2023, then plunged by 91.7% to $378587.0 in 2024, then slumped by 1925.51% to -$6.9 million in 2025.
- Business Quant data shows GRUSF's Gains from Investment Securities at -$6.9 million in Q2 2025, $1.2 million in Q1 2025, and $378587.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -6.91 Mn |
| Jun 30, 2025 | -6.91 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Sep 30, 2024 | 378,587.00 |
| Sep 30, 2024 | 378,587.00 |
| Jun 30, 2024 | 7.55 Mn |
| Jun 30, 2024 | 7.55 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Mar 31, 2024 | 5.66 Mn |
| Oct 31, 2023 | 4.56 Mn |
| Oct 31, 2023 | 4.56 Mn |
| Jul 31, 2023 | 679,322.00 |
| Jul 31, 2023 | 679,322.00 |
| Apr 30, 2023 | 270,712.00 |
| Apr 30, 2023 | 270,712.00 |
| Jul 31, 2021 | 422,867.00 |
| Jul 31, 2021 | 422,867.00 |
| Apr 30, 2021 | -253,300.00 |
| Apr 30, 2021 | -253,300.00 |